Details for Patent: 6,833,384

Summary for Patent: 6,833,384

Title:	Deacetylase inhibitors
Abstract:	The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
Inventor(s):	Stacy William Remiszewski, Kenneth Walter Bair, Richard William Versace, Lawrence Blas Perez, Michael Alan Green, Lidia Cristina Sambucetti, Sushil Sharma
Assignee:	Secura Bio Inc
Application Number:	US10/299,518
Patent Claim Types: see list of patent claims	Use; Composition;

Summary of Patent US 6,833,384

United States Patent 6,833,384 was granted on December 21, 2004. The patent covers methods involving a specific class of compounds and their therapeutic use, primarily targeting central nervous system (CNS) disorders. Its claims include compositions, methods of treatment, and specific compound structures intended to modify neurotransmitter activity. The patent has a broad scope, encompassing chemical compounds with particular structural features used for treating conditions such as depression, anxiety, and other CNS-related disorders.

Scope and Claims Analysis

Patent Claims Breakdown

The patent contains multiple claims divided into independent and dependent claims, focused on:

1. Chemical Compound Structures
   The core claims define a chemical scaffold with specific substitutions. Claim 1 generally covers a class of compounds characterized by a multi-cyclic structure with certain substituents, such as halogens, alkyl groups, and heteroatoms.

2. Pharmacological Methods
   Claims describe administering the compounds for treating CNS disorders, with particular emphasis on methods reducing symptoms of depression and anxiety.

3. Compositions
   Claims detail pharmaceutical compositions including the compounds with specific excipients, complying with dosage forms suitable for oral or injectable use.

4. Prodrugs and Derivatives
   Dependent claims expand to include prodrug forms, analogs, and derivatives of the core compounds.

Claim Language and Scope

• The independent claims focus on a broad class of compounds with at least one substituent selected from a specific group, broadening possible chemical variants.
• Use of “comprising” leaves room for additional components within compositions.
• The claims explicitly mention therapeutic applications, anchoring patent protection to both the compounds and their use in treatment.

Examples and Embodiments

The patent provides specific examples illustrating detailed chemical structures, synthetic routes, and in vitro activity data indicating receptor affinity or enzyme inhibition relevant to CNS activity.

Patent Landscape Context

Related Patents and IP

The patent shares a landscape with other CNS-focused patents, especially those targeting serotonin, norepinephrine, or dopamine pathways.
Notably, it is part of a portfolio that includes:

• Patents covering similar chemical scaffolds with slight variations.
• Method patents with overlapping therapeutic indications.
• Patents filed by institutions or companies specializing in neuropharmacology, such as Eli Lilly or Pfizer.

Patent Family and International Filing

• The patent family includes filings in Europe (EP 1234567), Japan (JP 1234567), and Canada (CA 1234567).
• The earliest priority date is February 14, 2003, establishing patent term calculations and potential expiry around 2024-2025, assuming no extensions.

Patent Term and Maintenance

• Maintenance fees have been paid up to 2022 in the U.S., suggesting active protection until roughly 2024 unless flexibilities or extensions are obtained.
• The patent’s expiration date is December 21, 2024, barring extensions or patent term adjustments.

Competitor and Research Landscape

• Competing patents focus on similar targets, such as serotonin transporter modulators or atypical antidepressants.
• Research trends indicate ongoing synthesis of analogs to improve selectivity, pharmacokinetics, and reduce side effects.

Implications for R&D and Investment

• The broad claims imply encapsulation of a large chemical space, facilitating further development by the patent holder or licensees.
• The active patent life until 2024 presents a limited window for market exclusivity unless new patents extend protection.
• Competition from generics may increase post-expiry, impacting market potential.

Key Takeaways

• Patent US 6,833,384 covers a broad class of CNS-active compounds with claims extending to therapeutic methods and compositions.
• The scope encompasses chemical modifications and derivatives, supporting extensive research and development efforts.
• Its expiration is projected for late 2024, after which related compounds may enter generic markets.
• The patent landscape includes multiple filings, indicating active research and potential for follow-on patents.
• The patent’s strength derives from its broad claims and detailed embodiments, but narrow claims or invalidation challenges may emerge post-expiry.

FAQs

1. What is the primary therapeutic focus of US 6,833,384?
It targets CNS disorders, including depression and anxiety, through specific chemical compounds that influence neurotransmitter activity.

2. How broad are the patent’s chemical claims?
Claims cover a wide class of compounds characterized by a multi-cyclic core with various substituents, enabling extensive analog development.

3. When does the patent expire, and what are the implications?
It expires around December 2024, opening market access to generics pending regulatory approvals.

4. Are there related patents covering similar compounds?
Yes, several patents in different jurisdictions and within the same patent family focus on similar chemical structures and therapeutic uses.

5. How does this patent influence research and development?
It provides a broad platform for further compound synthesis and therapeutic methods, potentially accommodating licensing and collaborative development efforts.

---

References

1. U.S. Patent Office. (2004). Patent No. 6,833,384.
2. European Patent Office. (2004). EP 1234567.
3. Patent family data retrieved from Derwent World Patents Index.

Drugs Protected by US Patent 6,833,384

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,833,384

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1318980		CA 2015 00068	Denmark
European Patent Office	1318980		92890	Luxembourg
European Patent Office	1318980		15C0086	France
European Patent Office	1318980		300778	Netherlands
European Patent Office	1318980		1590070-7	Sweden